Baker bros and Acadia., page-4

If you haven't done so yet, I highly encourage you all to looking into ACADIA management and board:

Board

Stephen R. Biggar, M.D., Ph.D. is a partner at Baker Brothers Investments ($15+ billion hedge fund).

Billionaire Julian C. Baker is a Managing Partner at Baker Brothers Investments. Mr. Baker and his brother Felix Baker, Ph.D., founded the firm in 2000.$15+ billion hedge fund.

If you do your DD you'd find Baker Bros. are well-known for their uncanny ability to unearth hidden gems in biotech and biopharma and would have been involved in the DD and decision to invest in and partner with neuren.

And I think, at these values, it is a fair bet they'll hit the Neuren register directly at some point.

Other board members FYI:

Jim Daly worked for Amgen, Inc. for ten years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK).

Edmund P. Harrigan, M.D. served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr. Harrigan’s previous executive leadership roles at Pfizer include serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development. Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years.

Daniel B. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States.

In summary, the team are solid with capabilities far beyond a specialtys pharma - more in line with big pharma capability wise

Cheers

5x8's